Why Is the Bacillus Calmette-Guerin BCG Vaccine Not Commonly Used in the United States: The TB Math, Trial Failures, and One Narrow Clinical Niche

The BCG vaccine isn't a routine childhood shot in the United States because the country's tuberculosis burden is too low for mass vaccination to pay off, and because the vaccine's protection is inconsistent enough that it would complicate the TB testing and treatment system Americans already rely on. That's the short version. What follows is the longer one — the actual numbers, the trial history, and the one place where BCG does get used in America every week.

The US instead runs what public health people call a "find and treat" strategy: screen for latent TB infection, then treat it before it becomes contagious. BCG interferes with exactly that machinery, since the standard skin test can't tell a vaccinated person from an infected one. And with roughly 8,000 to 10,000 TB cases reported annually nationwide in recent years, according to CDC surveillance data, the vaccine simply doesn't clear the bar that mass campaigns in high-burden countries do.

What BCG Actually Is and What It Was Built to Prevent

BCG is a live, weakened strain of Mycobacterium bovis, a cattle bacterium related to the TB organism. French researchers Albert Calmette and Camille Guérin attenuated it over 13 years of serial culturing starting around 1908, and the first human use came in 1921. It's among the oldest vaccines still in circulation — and one of the few named after its inventors rather than its target.

What it prevents matters more than most people assume. BCG's clearest, most consistent benefit is against disseminated TB in infants and young children, particularly tuberculous meningitis and miliary TB, which kill or disable quickly. Protection against pulmonary TB in adolescents and adults — the form that drives transmission — is far shakier and varies wildly by latitude, prior mycobacterial exposure, and the vaccine strain used.

That distinction is the whole ballgame for US policy. A vaccine that reliably protects infants from catastrophic TB but only sometimes protects adults from the contagious lung form looks very different in a country with 10 million annual cases than in one with under 10,000. Globally, the World Health Organization recommends BCG at birth in countries with high TB incidence; the US has never been on that list.

One more property shapes everything downstream: BCG is given intradermally, leaves a characteristic scar, and can produce a positive tuberculin skin test for years afterward. That last fact is the single biggest practical reason American clinicians avoid it in most patients.

The US Tuberculosis Burden Is Roughly a Thousandth of the Global Average

Here's the arithmetic that drives the policy. The WHO's Global Tuberculosis Report puts worldwide incidence near 130 cases per 100,000 people per year. The US rate sits around 2.5 to 3 per 100,000 — a difference of roughly 40 to 50 times, not the "thousandth" that casual comparisons sometimes imply. (I'd rather give you the defensible ratio than a dramatic one.)

Run the numbers on what mass infant vaccination would have to prevent. With about 3.6 million US births a year, vaccinating every newborn at an estimated $200 to $400 per dose plus administration — a range reflecting CDC vaccine contract pricing and clinic overhead, and worth confirming against current CDC price lists — costs somewhere between $700 million and $1.4 billion annually. Compare that to the total number of pediatric TB meningitis and miliary TB cases in the US each year, which CDC surveillance typically counts in the single digits to low dozens.

That doesn't pencil out even before you count the downstream costs: extra skin tests, chest X-rays, and interferon-gamma release assays (IGRAs) needed to sort out vaccine-induced positives in every future TB screening. The US Preventive Services Task Force and CDC both favor targeted testing of at-risk groups instead — people from high-burden countries, residents of congregate settings, health care workers, and close contacts of infectious cases.

Contrast that with a high-burden country: at 130 per 100,000, a birth cohort of 1 million faces thousands of infections and hundreds of pediatric TB deaths. There, even partial vaccine protection saves lives, and the WHO's recommendation holds. Same vaccine, different denominator.

The Great BCG Trial Split: Why Protection Ranges From 0% to 80%

The uncomfortable truth about BCG is that its efficacy estimates are all over the map, and the medical literature has never fully resolved why. The best-known analysis is a 1994 meta-analysis by Colditz and colleagues published in JAMA, which pooled trials and found protective efficacy against TB ranging from essentially zero to around 80%, with an overall estimate in the middle. The variability isn't noise — it's the story.

Several explanations compete. Latitude seems to matter: trials closer to the equator showed less protection, possibly because environmental mycobacteria there prime the immune system in ways that blunt BCG's effect. Different vaccine substrains — Copenhagen, Tokyo, Russia, Pasteur — are genetically distinct and may perform differently. Prior infection with related mycobacteria, host genetics, and trial methodology all contribute. No one has cleanly separated these factors.

For a national program, that kind of uncertainty is a management problem. A vaccine with 80% efficacy against a common disease is a triumph; the same vaccine with near-zero efficacy in some settings is a budget line that buys nothing. Countries with high TB burdens accept the gamble because the downside of doing nothing is worse. The US, facing a low burden, has the luxury of declining a bet with a wide confidence interval.

There's an edge case worth flagging: BCG's efficacy against TB meningitis in children is considerably more consistent than its efficacy against pulmonary disease, which is why even some lower-incidence countries have kept neonatal BCG. The US decision reflects the balance of all these considerations, not a claim that the vaccine never works.

The Skin Test Problem: BCG Blurs the Line Between Vaccination and Infection

Ask an American physician why they don't push BCG and you'll often hear one word: tuberculin. The Mantoux skin test works by injecting purified protein derivative and measuring the immune reaction. A prior BCG vaccination can produce a false-positive — a raised, reddened site that looks like latent TB infection but isn't.

That matters because the US strategy depends on the test's positive predictive value. In a low-prevalence population, even a modest false-positive rate swamps true positives. If you vaccinated millions of children, every subsequent TB screening in that cohort becomes ambiguous, triggering chest X-rays, IGRA blood tests (which are less affected by BCG but not perfectly so), and sometimes preventative antibiotic courses for people who were never infected.

The system-level cost is real and hard to quantify precisely, which is part of why it's rarely modeled. Consider a health care worker vaccinated as an infant abroad: their pre-employment screening typically routes to an IGRA rather than a skin test specifically because of BCG history. Scale that logic to an entire vaccinated population and the screening infrastructure strains. Countries that do mass vaccinate accept this tradeoff; the US chose not to create the problem.

Where BCG Does Show Up in American Medicine: Bladder Cancer

Here's the twist most people don't expect. BCG is used in the United States routinely — just not for TB. Intravesical BCG, instilled directly into the bladder, is a standard therapy for certain non-muscle-invasive bladder cancers, particularly carcinoma in situ and high-grade Ta or T1 tumors after resection. The immune stimulation that makes BCG a mediocre TB vaccine makes it a useful cancer immunotherapy.

The American Urological Association's guidelines list intravesical BCG as first-line therapy for these stages, with a typical induction course of six weekly instillations, sometimes followed by maintenance. It's not a trivial treatment: patients can experience cystitis-like symptoms, fever, and, rarely, systemic BCG infection requiring anti-tuberculosis drugs. But for the right tumor stage, it reduces recurrence and progression, and urologists use it constantly.

The supply side has been rocky. A global shortage of the Sanofi-produced strain (Immucyst) around 2012–2019 forced clinicians to ration doses, and the AUA issued guidance on triaging patients during shortages. Teva's strain and Merck's TICE strain have filled some of the gap, but availability remains a live concern that the urology community tracks closely. That fragility — one or two manufacturers, one specialized product — is itself a reason US clinicians think about BCG as a niche drug rather than a public health tool.

So the honest answer to "is BCG used in the US?" is yes, weekly, in urology clinics — and essentially never in pediatricians' offices.

The Catch-Up Problem: What Happens When an immigrant Arrives With a BCG Scar

Roughly a quarter of the world's population has received BCG, so American clinicians encounter vaccinated patients constantly — they just don't vaccinate them. The practical protocol matters: a documented BCG history is not a contraindication to TB testing, but it changes which test you order first. CDC guidance favors IGRAs for people likely to have been vaccinated, since the blood test uses antigens absent from BCG and most environmental mycobacteria.

The failure scenario worth knowing: a patient with a BCG scar and a positive skin test gets assumed to be "just vaccinated" and is not worked up further. That's a dangerous shortcut. BCG doesn't rule out latent infection, and a positive skin test in someone from a high-burden country should trigger evaluation regardless of vaccination history. Conversely, a negative IGRA in an actively symptomatic patient doesn't rule out TB either — no test does.

American clinicians also see BCG's rare complications: disseminated BCG infection in severely immunocompromised patients (a reason the vaccine is contraindicated in severe combined immunodeficiency), and local abscesses from poor injection technique abroad. These cases land in infectious disease clinics and require multidrug anti-TB regimens, which is a specialized skill set most US physicians rarely deploy.

Why Not Vaccinate Only High-Risk Groups?

A reasonable person might ask: fine, skip mass vaccination, but why not offer BCG to the highest-risk Americans — health care workers in TB wards, people traveling to high-burden countries, or infants in communities with elevated TB rates? This is where the policy gets more nuanced than "we just don't."

For travelers, the calculus is weak: BCG's protection against adult pulmonary TB is unreliable, and travelers can instead avoid exposure, use fit-tested respirators in high-risk settings, and get screened after return. The CDC's travel medicine guidance does not recommend BCG for most travelers, reserving consideration for long-term stays in high-risk settings and specific occupational exposures, and even then the evidence is thin.

For health care workers, the skin-test interference problem is decisive: a vaccinated nurse's annual screening becomes permanently complicated, and hospitals would rather screen than vaccinate. For high-risk infants, the numbers are simply too small to build a program around, and the infrastructure to identify and follow them doesn't exist at scale.

Selective vaccination is theoretically defensible. In practice, the US has decided the operational complexity exceeds the benefit, and the CDC's Advisory Committee on Immunization Practices has consistently leaned that way. That's a judgment call, not a law of nature — and it's worth knowing it's a call.

How the US Compares With Countries That Do Vaccinate

The clearest way to see the policy logic is side by side. The table below compares the two approaches on dimensions that actually drive decisions, using figures consistent with WHO and CDC publications; specific costs should be confirmed against current manufacturer and agency listings, since vaccine prices shift.

The comparison isn't about which country is smarter — it's about which strategy fits which epidemiology. A country with 130 per 100,000 incidence that skipped BCG would be committing a public health error; a country at 3 per 100,000 that mandated it would be spending heavily for marginal benefit while degrading its screening system.

The Newer Vaccines That Could Change the Math

BCG's weaknesses have driven a real research push, and the pipeline is the most interesting part of this story. Candidates like M72/AS01E, VPM1002, and BCG revaccination strategies have reported results suggesting better, more consistent protection against pulmonary TB in adults. If one of those succeeds at scale, the "BCG or nothing" framing dissolves.

That matters for the US question because the objection was never to vaccination in principle. It was to this vaccine's specific shortcomings: variable efficacy, skin-test interference, and a risk-benefit ratio that fails at low incidence. A vaccine with 50% consistent efficacy against adult pulmonary TB and no tuberculin cross-reactivity would get a serious look from ACIP even in a low-burden country, particularly for high-risk groups.

The timeline is uncertain and I won't pretend otherwise. Late-stage trials take years, and licensure is not guaranteed. But the honest framing is that the US decision is contingent on the current tool, not a permanent verdict on TB vaccination. Anyone tracking this should watch WHO and CDC advisory updates rather than assume the status quo is fixed.

What This Means If You're the One Making a Decision

If you're a clinician, the practical takeaway is simple: know your patient's BCG history, order an IGRA when it's relevant, and never let a scar substitute for a workup. If you're a traveler or an immigrant, understand that your vaccination doesn't exempt you from screening — it just changes which test comes first. If you're a policy-minded reader, the lesson is that vaccine decisions are arithmetic plus infrastructure, not ideology.

The one number to carry away: the US and the global average differ by a factor of roughly 40 to 50 in TB incidence. That gap explains almost everything about why the same vaccine is standard at birth in Manila and a niche urology drug in Minneapolis. The rest is detail — important detail, but detail.

For anyone weighing BCG for a specific patient or personal situation, the relevant authorities are the CDC's TB screening guidance, the ACIP recommendations, and the American Urological Association's bladder cancer guidelines. Those documents, not this article, should drive clinical decisions.

This article is general educational information about vaccine policy and tuberculosis prevention. It is not a diagnosis, treatment plan, or medical advice, and it makes no promise about outcomes from any vaccine or therapy. TB screening, BCG decisions, and bladder cancer treatment should be discussed with a qualified local clinician who knows your history and jurisdiction's guidance. If you have symptoms suggesting active TB — persistent cough, fever, night sweats, weight loss — seek medical care promptly; for immediate danger or self-harm risk, contact local emergency or crisis services.